Bill > HR2471

This bill seeks to improve the prevention and understanding of adverse drug events through several key provisions. It requires the Secretary of Health and Human Services to update the National Action Plan for Adverse Drug Event Prevention within 180 days, focusing on advances in pharmacogenomics (the study of how genes affect a person's response to drugs) and considering new scientific understanding of drug-gene interactions. The bill mandates the development of guidance for healthcare professionals on pharmacogenomic testing, including when to use genetic testing, how to incorporate it into medication management, and the importance of reporting genetic information related to adverse drug events. Additionally, the bill aims to improve electronic health record (EHR) systems by creating new certification criteria that would automatically alert healthcare providers about potential drug interactions based on a patient's genetic information. The legislation also calls for updates to the FDA Adverse Event Reporting System (FAERS), including creating patient-friendly reporting options and an optional tool to report drug-gene interactions. Furthermore, the bill requires a Government Accountability Office (GAO) study on how to include drug-gene interaction information on drug labels and mandates a report on potential improvements to EHR systems for capturing pharmacogenomic testing information. The overall goal is to enhance patient safety by leveraging genetic information to prevent adverse drug reactions.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/2471/all-info